The latest developments on Ebola, hepatitis B, long Covid
-
By
-
Theresa Gaffney
-
May 28, 2026
-
Clinical Scorecard: Recent Advances in Ebola, Hepatitis B, and Long COVID Research
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Ebola outbreak due to Bundibugyo ebolavirus; Hepatitis B treatment advancements; Long COVID prevalence (source needed). |
| Target Population | |
| Care Setting | |
Key Highlights
- Uganda closes border due to Ebola outbreak, contrary to WHO guidance (source needed).
- 1 in 6 COVID-19 patients develop long COVID, double previous estimates (source needed).
- Experimental drug shows 20% functional cure rate for chronic Hepatitis B (source needed).
Guideline-Based Recommendations
Diagnosis
Management
- No specific medications or vaccines for Bundibugyo ebolavirus (source needed).
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with chronic Hepatitis B.
20% of patients achieved functional cures in clinical trials.
Clinical Best Practices
- Follow WHO guidelines on travel restrictions during outbreaks (source needed).
Related Resources & Content
